Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

61. Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50

Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Translation of addendum A18-09 Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-50 (Version 1.0; Status: 23 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 23 February 2018 1.0 Commission: A18-09 Version: Status: IQWiG Reports (...) – Commission No. A18-09 Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Addendum A18-09 Version 1.0 Atezolizumab – Addendum to Commission A17-50 23 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

62. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib Brigatinib for treating ALK Brigatinib for treating ALK-positiv -positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer after crizotinib after crizotinib T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta571 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

63. Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67

Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67 1 Translation of addendum A18-30 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-67 (Version 1.0; Status: 1 June 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 1 June 2018 1.0 Commission: A18-30 Version: Status: IQWiG Reports – Commission No. A18-30 (...) Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 1 Addendum A18-30 Version 1.0 Alectinib – Addendum to Commission A17-67 1 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 Commissioning agency: Federal Joint Committee Commission awarded on: 8 May 2018 Internal Commission No.: A18-30 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

64. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. (Abstract)

Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Pulmonary complications are often seen during the postoperative period following lung resection for patients with lung cancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive pressure ventilation (NIPPV (...) ) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015.To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer.We searched the Cochrane Central Register

2019 Cochrane

65. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Full Text available with Trip Pro

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion

2019 EvidenceUpdates

66. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) Dabr Dabrafenib with tr afenib with trametinib for treating ametinib for treating advanced metastatic BRAF V600E advanced metastatic BRAF V600E mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer (terminated appr cancer (terminated appraisal) aisal) T echnology appraisal guidance Published: 27 February 2019 nice.org.uk (...) /guidance/ta564 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non- small-cell lung cancer (terminated appraisal) (TA564) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

67. Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review (Abstract)

Combining smoking cessation interventions with LDCT lung cancer screening: A systematic review Providing smoking cessation treatment with annual low dose CT (LDCT) screening offers an opportunity to reduce smoking-related morbidity and mortality. However, the optimal approach for delivering cessation interventions in the LDCT screening context is unknown. We searched for randomized controlled trials and observational studies with a control group testing a smoking cessation intervention among

2019 EvidenceUpdates

68. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. Full Text available with Trip Pro

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. 30667494 2019 02 19 2019 07 23 1538-3598 321 3 2019 01 22 JAMA JAMA Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. 306-307 10.1001/jama.2018.18085 Denis Fabrice F Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France. Basch Ethan E Lineberger Comprehensive Cancer Center, University of North (...) Internet Kaplan-Meier Estimate Lung Neoplasms diagnosis diagnostic imaging mortality Neoplasm Recurrence, Local diagnosis Population Surveillance methods Self Report Symptom Assessment methods 2019 1 23 6 0 2019 1 23 6 0 2019 3 21 6 0 ppublish 30667494 2721170 10.1001/jama.2018.18085 PMC6439676

2019 JAMA Controlled trial quality: uncertain

69. Exercise training for advanced lung cancer. Full Text available with Trip Pro

Exercise training for advanced lung cancer. Patients with advanced lung cancer have a high symptom burden, which is often complicated by coexisting conditions. These issues, combined with the indirect effects of cancer treatment, can cumulatively lead patients to continued deconditioning and low exercise capacity. This is a concern as exercise capacity is considered a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult (...) treatments. There is evidence that exercise training improves exercise capacity and other outcomes, such as muscle force and health-related quality of life (HRQoL), in cancer survivors. However, the effectiveness of exercise training on these outcomes in people with advanced lung cancer is currently unclear.The primary aim of this review was to investigate the effects of exercise training on exercise capacity in adults with advanced lung cancer. Exercise capacity was defined as the six-minute walk

2019 Cochrane

70. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Full Text available with Trip Pro

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum

2019 EvidenceUpdates

71. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study Full Text available with Trip Pro

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study The US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lung cancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lung cancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume

2019 EvidenceUpdates

72. Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2019 Health Canada - Drug and Health Product Register

73. Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database (Abstract)

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lung cancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lung cancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6

2019 EvidenceUpdates

74. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Whole brain radiotherapy provides little benefit for lung cancer that has spread Discover Portal Discover Portal Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 doi: Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated on. This mainly UK-based trial (...) found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message that this treatment has little

2019 NIHR Dissemination Centre

75. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Discover Portal Discover Portal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 doi: Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been removed by surgery. Just (...) recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lung cancers

2019 NIHR Dissemination Centre

76. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. Full Text available with Trip Pro

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type.Nested case-control study.20 population based cohort studies in Asia, Europe, Australia (...) , and the United States.5299 patients with incident lung cancer, with individually incidence density matched controls.Circulating hsCRP concentrations in prediagnostic serum or plasma samples.Incident lung cancer diagnosis.A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P

2019 BMJ

77. Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

78. A systematic review and network meta-analysis of bone-modifying agents for metastatic lung cancer

A systematic review and network meta-analysis of bone-modifying agents for metastatic lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

79. Systematic review and meta-analysis of Icotinib versus pemetrexed in treated non-small-cell lung cancer

Systematic review and meta-analysis of Icotinib versus pemetrexed in treated non-small-cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

80. Prognostic value of immunohistochemical detection of carcinoma-associated fibroblasts in non-small cell lung cancer: a systematic review and meta-analysis

Prognostic value of immunohistochemical detection of carcinoma-associated fibroblasts in non-small cell lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO